Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

Objective: The metabolic benefits of GLP-1 receptor (GLP-1R) agonists on glycemic and weight control are well established as therapy for type 2 diabetes and obesity. Glucagon's ability to increase energy expenditure is well described, and the combination of these mechanisms-of-actions has the p...

Full description

Bibliographic Details
Main Authors: Thomas Monfeuga, Jenny Norlin, Anne Bugge, Elisabeth D. Gaalsgaard, Cesar A. Prada-Medina, Markus Latta, Sanne S. Veidal, Pia S. Petersen, Michael Feigh, Dorte Holst
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Molecular Metabolism
Subjects:
GLP1R/GCGR agonist
Hepatic steatosis
Fibrogenesis
Transcriptome profiling
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877823001849

Internet

http://www.sciencedirect.com/science/article/pii/S2212877823001849

Similar Items